Protalix BioTherapeutics, Inc. (PLX) Form 10-Q — Aug 12, 2026
Protalix BioTherapeutics (PLX) reported first-half 2026 revenue of $53.6 million, up from $25.8 million a year earlier, driven primarily by a $25.0 million milestone payment from Chiesi following EU approval of Elfabrio's 2 mg/kg every-four-week dosing regimen. Selling-goods revenue rose a more modest ~7% to $27.2 million on stronger Chiesi and Fiocruz sales, partially offset by lower Pfizer orders. The company swung to net income of $22.1 million ($0.28 basic EPS) from a $3.5 million loss in the prior-year period, and operating cash flow turned positive at $11.6 million versus a $10.3 million outflow a year ago. Q2 2026 net income was $3.8 million on revenue of $19.9 million.
Key figures
- Eps
- 0.28
- Revenue
- 53646000
- Net Income
- 22094000
- Revenue Yoy
- +108% (H1 2026 $53.6M vs H1 2025 $25.8M)
- Cash Position
- 40700000
- Shares Outstanding
- 80571642
- Total assets
- 110336000
- H1 2025 revenue
- 25771000
- Q2 2026 revenue
- 19896000
- Q2 2026 basic eps
- 0.05
- Q2 2026 net Income
- 3777000
- Rd expenses h1 2026
- 9777000
- Rd grant recognized
- 2100000
- Atm capacity remaining
- 15700000
- Cost of revenues h1 2026
- 11889000
- Short term bank deposits
- 13236000
- Cash and equivalents only
- 27420000
- Operating cash flow h1 2026
- 11625000
- Selling goods revenue h1 2026
- 27247000
- Remaining chiesi milestones us
- 740000000
- Chiesi milestone received q1 2026
- 25000000
- Remaining chiesi milestones ex us
- 270000000
- License and rd services revenue h1 2026
- 26399000
Price after filing
Close on the filing date to close N calendar days later (from $2.62). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.